Pfizer PFE is facing one of the steepest patent cliffs in the large-cap pharma space. The company expects a significant ...

Pfizer Inc. (NYSE:PFE) ranks among the best retirement stocks to buy now. On May 5, BofA Securities boosted its price ...

Pfizer Inc. (NYSE:PFE) is one of the best medical stocks to invest in according to billionaires. Pfizer Inc. (NYSE:PFE) ...

Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...

The pharmaceutical powerhouse still faces plenty of patent challenges, but it got a big one out of the way, securing time and ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Pfizer’s implied fair value per share has edged up from US$29.08 to US$29.19, while some price targets on the stock cluster ...

Is Pfizer a yield trap? No way.

Dividend investors will focus on Pfizer's current dividend yield of 6.3%. The stock has offered high yields before, averaging about 4% over the past decade. However, the current yield is significantly ...

The company contradicts claims made by Netanyahu during the election campaign about research and development centers in Israel.

Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...